Founder launches new biotech to scale personalized medicines after prior venture folded

Julia Vitarello’s daughter Mila received a custom‑designed therapy for her rare mutation eight years ago, sparking Vitarello’s interest in individualized treatments.

Her first company, EveryONE Medicines, shut down after new FDA guidance on bespoke therapies failed to create a clear investment pathway, according to Vitarello.

She is now assembling a new biotech aimed at producing personalized medicines at a larger scale and is actively seeking fresh funding partners.

The move highlights ongoing commercial and regulatory obstacles that companies face when trying to bring patient‑specific drugs to market.